Earlier this week, the United States Food and Drug Administration (FDA) approved a human trial for a blueberry-sized brain ...

In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin therapy COMP360 in treatment-resistant depression and selected it for the ...

The newly approved device aims to treat depression by directly stimulating neural activity.

Brain implant gets FDA clearance for first wireless depression treatment trial, offering battery-free stimulation in ...

The FDA’s move follows an executive order from President Donald Trump earlier this month that paved the way for more ...

TRENTON, N.J. (AP) — The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth. The agency on Tuesday approved Sage Therapeutics' ...

Curio Digital Therapeutics Inc.’s MamaLife Plus offers a nonpharmaceutical alternative to treating postpartum depression. Last month, it because the first prescription digital therapeutic (PDT) ...

A device the size of a blueberry is hypothesized to give people with treatment-resistant depression another option — and the FDA is giving its Houston maker a chance to test it.

NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to help ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...

Texas is helping shape the future of psychedelic therapies. Here's how they work and what access could look like.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images. Major ...